However, anticoagulation cuts risk for major thromboembolic events by 46 percent
MONDAY, April 12, 2021 (HealthDay News) — Following COVID-19 hospitalization, thromboembolic events occur frequently, according to a study published online April 6 in Blood.
Dimitrios Giannis, M.D., from The Feinstein Institutes for Medical Research at Northwell Health in Manhasset, New York, and colleagues used data from 4,906 consecutive COVID-19 patients (53.7 percent male; mean age, 61.7 years) hospitalized within a multihospital system from March 1 to May 31, 2020. The authors examined the frequency of postdischarge thromboembolic events (venous thromboembolism [VTE], arterial thromboembolism [ATE], and all-cause mortality).
The researchers found that postdischarge thromboprophylaxis was prescribed in 13.2 percent and the composite primary outcome rate was 7.13 percent (VTE, 1.55 percent; ATE, 1.71 percent; all-cause mortality, 4.83 percent; major bleeding, 1.73 percent). The composite primary outcome was significantly associated with advanced age (odds ratio [OR], 3.66), prior VTE (OR, 2.99), intensive care unit stay (OR, 2.22), chronic kidney disease (OR, 2.10), peripheral arterial disease (OR, 2.04), carotid occlusive disease (OR, 2.02), IMPROVE-DD VTE score ≥4 (OR, 1.51), and coronary artery disease (OR, 1.50). After discharge, reduced rates of the primary outcome were associated with anticoagulation (OR, 0.54).
“This study reveals it is important to monitor COVID-19 survivors for dangerous blood clots even after they leave the hospital,” Kevin J. Tracey, M.D., chief executive officer of the Feinstein Institutes, said in a statement.
Abstract/Full Text (subscription or payment may be required)
~16 Percent of COVID Cases Develop Postacute Sequelae of SARS-CoV-2
New Guideline Details Diagnosis, Treatment of Acute Pulmonary Embolism
Guideline Updated for Early Management of Acute Ischemic Stroke
Continuing Oral Anticoagulants After ≥90 Days Tied to Lower Risk for Recurrent VTE
Elevated INR in Older Adults on Warfarin May Not Be Tied to Risk for Brain Bleeding After Head Trauma
Bleeding Risks for Oral Anticoagulants and Aspirin Mostly Similar
Fewer Bleeding Events Seen With Abelacimab Than Rivaroxaban in A-Fib